MONMOUTH JUNCTION, N.J.,
July 26, 2011 /PRNewswire/ -- Insmed
Incorporated (Nasdaq CM: INSM), a biopharmaceutical company, will
host a conference call on Monday, August
8th, 2011, at 8:30 AM ET, to
discuss its financial results for the second quarter of 2011.
Insmed intends to issue its quarterly financial results press
release before the market opens on August
8th.
To participate in the live conference call, please dial
800-901-5247 (U.S. callers) or 617-786-4501 (international), and
provide passcode 14391743. A live webcast of the call will
also be available at
http://phx.corporate-ir.net/playerlink.zhtml?c=122332&s=wm&e=4160458.
Please allow extra time prior to the webcast to register,
download and install any necessary audio software.
The webcast will be archived for 30 days, and a telephone replay
of the call will be available for seven days, beginning at
11:30 AM ET on August 8th, at 888-286-8010 (U.S. callers) or
617-801-6888 (international), using passcode 57316274.
About Insmed
Insmed Incorporated is a biopharmaceutical company focused on
the development of innovative inhaled pharmaceuticals for the
site-specific treatment of serious lung diseases, and has a
proprietary protein platform aimed at niche markets with unmet
medical need. Insmed's primary focus is on the development of
inhaled antibiotic therapy delivered via proprietary advanced
pulmonary liposome technology in areas of high unmet need in lung
diseases. For more information, please visit
http://www.insmed.com.
Forward-Looking Statements
This release contains forward-looking statements which are made
pursuant to provisions of Section 21E of the Securities Exchange
Act of 1934. Investors are cautioned that such statements in this
release, including statements relating to our financial positions,
results of operations, the results of clinical trials and clinical
data described herein, the development of our products, and the
business strategies, plans and objectives of management, constitute
forward-looking statements which involve risks and uncertainties
that could cause actual results to differ materially from those
anticipated by the forward-looking statements. Our results
may be affected by such factors as the receipt and timing of FDA
and other regulatory approvals, if at all, competitive developments
affecting our product development, delays in product development or
clinical trials, and patent disputes involving currently developing
products. The risks and uncertainties include, without
limitation, our future clinical trials may not support the data
described in this release, we may be unsuccessful in developing our
product candidates or receiving necessary regulatory approvals, we
may experience delays in our product development or clinical
trials, our product candidates may not prove to be commercially
successful, our expenses may be higher than anticipated and other
risks and challenges detailed in our filings with the U.S.
Securities and Exchange Commission, including our Annual Report on
Form 10-K for the year ended December 31,
2010. Investors are cautioned not to place undue
reliance on any forward-looking statements which speak only as of
the date of this release. We undertake no obligation to
publicly release the results of any revisions to these
forward-looking statements that may be made to reflect events or
circumstances that occur after the date of this release or to
reflect the occurrence of unanticipated events.
Investor Relations Contact:
Brian Ritchie - FD
212-850-5683
brian.ritchie@fd.com
Media Contact:
Irma Gomez-Dib - FD
212-850-5761
irma.gomez-dib@fd.com
SOURCE Insmed Incorporated